Oppenheimer Lowers TransMedics Group (NASDAQ:TMDX) Price Target to $125.00

TransMedics Group (NASDAQ:TMDX) had its price target decreased by Oppenheimer from $200.00 to $125.00 in a report published on Tuesday, Marketbeat Ratings reports. Oppenheimer currently has an outperform rating on the stock.

TMDX has been the subject of a number of other reports. Morgan Stanley raised their price target on TransMedics Group from $104.00 to $145.00 and gave the stock an “equal weight” rating in a research note on Monday, July 15th. Needham & Company LLC cut their price target on shares of TransMedics Group from $208.00 to $109.00 and set a “buy” rating on the stock in a report on Tuesday. Robert W. Baird assumed coverage on shares of TransMedics Group in a report on Tuesday, September 24th. They set an “outperform” rating and a $200.00 price objective for the company. Piper Sandler reissued an “overweight” rating and issued a $180.00 price objective on shares of TransMedics Group in a research report on Monday, October 7th. Finally, Canaccord Genuity Group raised their target price on shares of TransMedics Group from $117.00 to $169.00 and gave the stock a “buy” rating in a research report on Thursday, August 1st. One investment analyst has rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, TransMedics Group presently has an average rating of “Buy” and an average price target of $144.80.

TransMedics Group Trading Down 29.9 %

TMDX stock opened at $88.50 on Tuesday. The firm’s fifty day simple moving average is $146.02 and its two-hundred day simple moving average is $140.16. The stock has a market capitalization of $2.95 billion, a price-to-earnings ratio of 94.15 and a beta of 1.99. The company has a quick ratio of 8.48, a current ratio of 9.37 and a debt-to-equity ratio of 2.67. TransMedics Group has a twelve month low of $36.42 and a twelve month high of $177.37.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.16). The firm had revenue of $108.76 million during the quarter, compared to analysts’ expectations of $115.00 million. TransMedics Group had a return on equity of 15.98% and a net margin of 0.84%. The business’s revenue for the quarter was up 63.7% compared to the same quarter last year. During the same period last year, the company earned ($0.12) earnings per share. As a group, analysts anticipate that TransMedics Group will post 1.22 earnings per share for the current year.

Insider Activity

In other TransMedics Group news, insider Tamer I. Khayal sold 2,958 shares of the company’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $156.77, for a total transaction of $463,725.66. Following the completion of the sale, the insider now owns 20,843 shares in the company, valued at $3,267,557.11. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO Waleed H. Hassanein sold 8,625 shares of the business’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the completion of the transaction, the chief executive officer now owns 61,643 shares in the company, valued at $9,457,269.06. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Tamer I. Khayal sold 2,958 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $156.77, for a total transaction of $463,725.66. Following the completion of the sale, the insider now owns 20,843 shares of the company’s stock, valued at approximately $3,267,557.11. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 64,205 shares of company stock worth $9,981,907. Corporate insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

A number of large investors have recently made changes to their positions in the business. International Assets Investment Management LLC purchased a new position in TransMedics Group during the 2nd quarter worth $47,000. USA Financial Formulas purchased a new stake in shares of TransMedics Group during the third quarter worth about $55,000. J.Safra Asset Management Corp increased its holdings in shares of TransMedics Group by 649.2% during the second quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock valued at $67,000 after acquiring an additional 383 shares in the last quarter. Signaturefd LLC raised its position in shares of TransMedics Group by 26.6% in the 2nd quarter. Signaturefd LLC now owns 443 shares of the company’s stock valued at $67,000 after purchasing an additional 93 shares during the last quarter. Finally, Fidelis Capital Partners LLC acquired a new stake in TransMedics Group in the 1st quarter worth approximately $35,000. 99.67% of the stock is owned by institutional investors and hedge funds.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.